Molecular Partners AG | Ownership
Companies that own Molecular Partners AG
BVF Partners LP
900,000
4.24%
-53,320
1.34%
12/31/2017
Pictet Asset Management SA
643,935
3.04%
0
0.02%
12/31/2017
Vontobel Asset Management AG
629,353
2.97%
-425
0.09%
07/31/2018
UBS AG (Investment Management)
561,037
2.64%
30,084
0.01%
09/04/2018
GAM Investment Management (Switzerland) AG
552,098
2.6%
-1,195
0.18%
05/31/2018
Zürcher Kantonalbank (Investment Management)
409,549
1.93%
570
0.03%
07/31/2018
UBP-Gestion Institutionnelle SA
350,495
1.65%
-4,449
0.41%
12/31/2017
Credit Suisse Asset Management (Schweiz) AG
143,946
0.68%
-2,518
0.01%
06/29/2018
Baillie Gifford & Co.
96,900
0.46%
12,635
0%
04/30/2018
BlackRock Fund Advisors
75,559
0.36%
0
0%
09/06/2018
| Address |
Wagistrasse 14
Zurich Zurich 8952
Switzerland
|
|
Employees
|
- |
| Website |
http://www.molecularpartners.com |
| Updated |
07/08/2019 |
| Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun and Michael Tobias Stumpp on November 23, 2004 and is headquartered in Zurich, Switzerland. |
